{"id":72441,"date":"2026-08-13T17:35:21","date_gmt":"2026-08-13T09:35:21","guid":{"rendered":"https:\/\/flcube.com\/?p=72441"},"modified":"2026-08-13T17:35:22","modified_gmt":"2026-08-13T09:35:22","slug":"youcare-pharmaceuticals-ykyy033-sirna-injection-wins-us-fda-approval-to-conduct-clinical-trials-for-arterial-and-venous-thrombosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72441","title":{"rendered":"Youcare Pharmaceutical&#8217;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Youcare Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688658:SHA\">SHA: 688658<\/a>) announced that <strong>YKYY033 injection<\/strong> has received approval from the <strong>US Food and Drug Administration (FDA)<\/strong> to conduct <strong>clinical trials<\/strong> for the <strong>prevention and treatment of arterial and venous thrombosis<\/strong>, advancing the company&#8217;s siRNA candidate against coagulation factor XI (FXI) into US clinical development.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Youcare Pharmaceutical (SHA: 688658)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>US FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>YKYY033 injection<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention and treatment of arterial and venous thrombosis<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>Phase 1 study approved by NMPA; currently progressing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-ykyy033\" class=\"wp-block-heading\">Drug Profile \u2013 YKYY033<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> Chemically synthesized <strong>double-stranded siRNA<\/strong> drug conjugated with an <strong>N-acetylgalactosamine (GalNAc) ligand<\/strong><\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Silences messenger RNA (mRNA) transcribed from the <strong>coagulation factor XI (FXI) gene<\/strong> through <strong>RNA interference<\/strong>, inhibiting FXI protein production at the source<\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> FXI inhibition is a leading strategy for anticoagulants that aim to prevent thrombosis <strong>without increasing bleeding risk<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-profile\" class=\"wp-block-heading\">Preclinical Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>FXI Suppression<\/strong><\/td><td>Significantly reduces FXI protein levels and activity across various animal models<\/td><\/tr><tr><td><strong>Coagulation Effect<\/strong><\/td><td>Efficiently and durably prolongs <strong>APTT<\/strong> without affecting <strong>prothrombin time (PT)<\/strong> \u2014 demonstrating specific inhibition of the <strong>intrinsic coagulation pathway<\/strong><\/td><\/tr><tr><td><strong>Antithrombotic Efficacy<\/strong><\/td><td>Significant antithrombotic efficacy in thrombus models <strong>without increasing bleeding risk<\/strong><\/td><\/tr><tr><td><strong>Toxicology<\/strong><\/td><td>Repeat-dose toxicity studies indicate a favorable safety and tolerability profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Market Clinical Pathway:<\/strong> With the FDA clearance joining an <strong>NMPA-approved Phase 1 study already progressing in China<\/strong>, YKYY033 is positioned for parallel US-China development \u2014 a structure that broadens partnership and licensing optionality.<\/li>\n\n\n\n<li><strong>FXI: A Crowded but Validated Battleground:<\/strong> Factor XI has become one of anticoagulation&#8217;s most sought-after targets as the field pursues safer alternatives to factor Xa and thrombin inhibitors, which carry inherent bleeding liability.<\/li>\n\n\n\n<li><strong>siRNA Differentiation:<\/strong> A GalNAc-conjugated siRNA approach to FXI offers the potential for <strong>durable, infrequently dosed anticoagulation<\/strong>, distinguishing YKYY033 from small-molecule and antibody FXI candidates in development.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Trial design, dosing schedules, and timelines for first patient dosing in the US were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the clinical development potential of YKYY033. Actual results may differ due to risks including clinical progress, safety outcomes, and competitive dynamics in anticoagulation therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688658_20260813_92B1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688658_20260813_92B1.\"><\/object><a id=\"wp-block-file--media-93419fa4-9a7f-451d-aea3-63d3f79635cd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688658_20260813_92B1.pdf\">688658_20260813_92B1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688658_20260813_92B1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-93419fa4-9a7f-451d-aea3-63d3f79635cd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,64,1807,1808],"class_list":["post-72441","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-rnai-aso","tag-sha-688658","tag-youcare-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Youcare Pharmaceutical&#039;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company&#039;s siRNA candidate against coagulation factor XI (FXI) into US clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72441\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Youcare Pharmaceutical&#039;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis\" \/>\n<meta property=\"og:description\" content=\"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company&#039;s siRNA candidate against coagulation factor XI (FXI) into US clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72441\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T09:35:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T09:35:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Youcare Pharmaceutical&#8217;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis\",\"datePublished\":\"2026-08-13T09:35:21+00:00\",\"dateModified\":\"2026-08-13T09:35:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"RNAi \\\/ ASO\",\"SHA: 688658\",\"Youcare Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72441#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72441\",\"name\":\"Youcare Pharmaceutical's YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T09:35:21+00:00\",\"dateModified\":\"2026-08-13T09:35:22+00:00\",\"description\":\"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company's siRNA candidate against coagulation factor XI (FXI) into US clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72441\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72441#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Youcare Pharmaceutical&#8217;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Youcare Pharmaceutical's YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis - Insight, China&#039;s Pharmaceutical Industry","description":"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company's siRNA candidate against coagulation factor XI (FXI) into US clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72441","og_locale":"en_US","og_type":"article","og_title":"Youcare Pharmaceutical's YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis","og_description":"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company's siRNA candidate against coagulation factor XI (FXI) into US clinical development.","og_url":"https:\/\/flcube.com\/?p=72441","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T09:35:21+00:00","article_modified_time":"2026-08-13T09:35:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72441#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72441"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Youcare Pharmaceutical&#8217;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis","datePublished":"2026-08-13T09:35:21+00:00","dateModified":"2026-08-13T09:35:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72441"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","RNAi \/ ASO","SHA: 688658","Youcare Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72441#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72441","url":"https:\/\/flcube.com\/?p=72441","name":"Youcare Pharmaceutical's YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T09:35:21+00:00","dateModified":"2026-08-13T09:35:22+00:00","description":"Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials for the prevention and treatment of arterial and venous thrombosis, advancing the company's siRNA candidate against coagulation factor XI (FXI) into US clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72441#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72441"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72441#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Youcare Pharmaceutical&#8217;s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72441"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72441\/revisions"}],"predecessor-version":[{"id":72449,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72441\/revisions\/72449"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}